Zelboraf
vemurafenib · Roche Registration GmbH
AUTHORISED IN THE EUWhat Zelboraf is used for
Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Zelboraf
- Active substance
- vemurafenib
- Disease area
- Melanoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01EC01
- Marketing authorisation holder
- Roche Registration GmbH
- Authorised in the EU since
- 2012
Official information
In the USA
Same active substance: Zelboraf
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zelboraf used for?
Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
What is the active substance in Zelboraf?
Zelboraf contains vemurafenib.
Who makes Zelboraf?
The EU marketing authorisation holder is Roche Registration GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU